NEWS
Basel, 6 December 2001
Roche renews support for Roche Organ Transplantation
Research Foundation for a further three years
Roche announced today that it will extend the support
for the Roche Organ Transplantation Research Foundation
(ROTRF) for a further three years until 2006. The five
million Swiss franc annual donation to the independent
research foundation was established in 1998 for an
initial period of five years. This new extension
demonstrates a long-term commitment to research to
improve the life for thousands of patients undergoing
organ transplantations every year.
ROTRF is an independent charity, which directly supports
innovative research projects attracting new researchers
with innovative and novel scientific ideas to meet unmet
medical needs in solid organ transplantation.
Prof. Phil Halloran, Chairman of the Board of Trustees
said: “We are deeply grateful to Roche for the continued
commitment to this Foundation. ROTRF will be able to
fund and promote research in many countries with these
new funds, and patients undergoing organ transplants
will ultimately benefit. The knowledge generated from
this research will have spin-off benefits for other
disciplines.”
William M. Burns, Head of Roche’s Pharmaceuticals
Division, said: “Roche has been very impressed at the
calibre of studies being supported by the ROTRF, and the
decision to extend the financial support of the
Foundation reflects the commitment of Roche to the
Transplantation community. We are proud of our
association to this worthy Foundation.”
Roche in transplantation
Roche continues to expand its commitment to improve
the long-term outcomes of transplantation while
enhancing the quality of life for the patient. Roche has
developed three innovative therapies that improve graft
and post-transplant health: CellCept and Zenapax prevent
the acute rejection of the newly transplanted organ,
offering both physicians and patients the possibility of
a low toxicity immunosuppressive regimen, and
Cymevene/Cytovene, developed for the prevention and
treatment of cytomegalovirus infection.
Email This Page
Print
This Page
|
|
| |
NEWS & EVENTS
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum
16.11.2005
MabThera – a unique approach providing lasting
benefits for patients with rheumatoid arthritis
Comprehensive long-term clinical success achieved in
difficult-to-treat patients following just two
administrations, two weeks apart
›
more
|
|
 |
| |
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum
06.09.2005
Roche files first rheumatoid arthritis indication for
MabThera in Europe
MabThera: a medicine used to treat non-Hodgkin's
lymphoma
MabThera delivers significant and sustained relief from
symptoms in patients with difficult-to-treat rheumatoid
arthritis.
›
more
|
|
|
|
| |
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum
06.04.2005
MabThera significantly improves symptoms in patients
with rheumatoid arthritis who inadequately responded to
anti-TNFα therapies
Third large randomised trial to evaluate efficacy and
safety of MabThera in RA
Roche, Genentech and Biogen Idec announced today that
REFLEX1, a pivotal Phase III study of MabThera (rituximab), successfully met its
primary endpoint in the group of patients with the most difficult-to-treat
rheumatoid arthritis (RA).
›
more
|
|
 |
Legal Disclamer
|
Legal Disclaimer
Copyright
©WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune
Diseases.
This Web site was developed in 2005 as a service provided by the
WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune
Diseases. This Web site provides selected information available
about lupus and arthritis. It is important that public see a
healthcare professional for detailed information about medical
conditions and treatment. This information is not intended to be a
substitute for the advice of a healthcare professional, or a
recommendation for any particular treatment plan. The WHO-ILAR
COPCORD Stage II Education on Treatment of the Autoimmune Diseases
has made and will continue to make efforts to include accurate and
up-to-date information on this Web site.
If you have any
questions, please contact us:
Webmaster
Phone: 62-24-8447-345
Fax: 62-24-8310-028
admin@LupusArthritisIndonesia.org
|
|
